This article was originally published by Ekaterina Galkina Cleary, Jennifer M. Beierlein, Navleen Surjit Khanuja, Laura M. McNamee and Fred D. Ledley in PNAS under a Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC…
The po…
Contribution of NIH funding to new drug approvals 2010–2016 Read Post »
Without a strong biosimilars market, costs for biologics in the US continue trending upward. The world of drug patents for biosimilars in the United States is far more complex than…
The post Understanding the Barriers to US Biosimilars appeared …
Annual Drug Patent Expirations for SOLODYN Solodyn is a drug marketed by Medicis and is included in one NDA. It is available from three suppliers. There are nine patents protecting…
The post New patent expiration for Medicis drug SOLODYN appeared…
Annual Drug Patent Expirations for XIMINO Ximino is a drug marketed by Sun Pharm Inds Ltd and is included in one NDA. It is available from one supplier. There are…
The post New patent expiration for Sun Pharm drug XIMINO appeared first on DrugPat…
Formularies come into effect at the hospital level and the individual insurer level When developed and managed with due care and consideration, drug formularies can be a good tool for…
The post Formulary Decisions: Exploring the Ethics of Drug Ap…
Formulary Decisions: Exploring the Ethics of Drug Approval Read Post »
MAKE BETTER DECISIONS Join the 500+ leading biopharmaceutical companies we have served and make better decisions with DrugPatentWatch’s deep knowledge on biologic and small molecule drugs. Check out our flexible…
The post Make Better Decisions With Dru…
Although currently tiny and narrowly focused on a handful of disease areas and countries, the biosimilar industry is set to expand as patents expire on top biologics, payers push for…
The post Top 5 Challenges Faced By Biosimilars appeared first …
For the last century, drug development consisted of tiny-molecule treatments focused at mass audience. It worked for some patients while it didn’t for the rest. In some cases, we knew…
The post Top 6 issues facing the biotechnology industry appea…
This article was originally published by Christopher Southan, Peter Varkonyi, Kiran Boppana, Sarma A.R.P. Jagarlapudi, and Sorel Muresan at PLoS ONE 8(10): e77142. Abstract The statistics of drug development output and…
The post Tracking 20 Years…
Tracking 20 Years of Compound-to-Target Output from Literature and Patents Read Post »
By Larry Ramer, DrugPatentWatch writer Artificial intelligence, or AI, has advanced significantly in recent years and could significantly lower pharma companies’ R&D costs by enabling precision medicine and greatly reducing…
The post Can Arti…
Can Artificial Intelligence Help Drug Development? Read Post »